Merck Provides Update on Strategic Actions to Transform the Company and Build a Platform for Sustained Future Growth at the 33rd Annual J.P. Morgan Healthcare Conference
Dateline City:
KENILWORTH, N.J.
KEYTRUDA, First FDA-Approved Anti-PD-1 Therapy, Filed and Launched Within Five Months
Company Expects to Submit sBLA for KEYTRUDA in Mid-Year 2015 for Advanced Non-Small Cell Lung Cancer
NDA Submission for Hepatitis C Combination Regimen, Grazoprevir/Elbasvir (MK-5172/MK-8742), Planned for First Half of 2015
Seven New Products were Approved in 2014
Company Announced Acquisition of Cubist, Acquired Idenix and Divested its Consumer Care Business
Targeted Cost Savings are on Track to be Realized by the End of 2015
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today will report on the ongoing execution of its multi-year, strategic
initiative to sharpen its commercial and research and development (R&D)
focus, redesign its operating model and reduce its cost base. In October
2013, Merck launched its global initiative
to transform the company into a more competitive and innovative company
and to build a platform for sustained future growth.
Language:
English
Contact:
Merc...
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Conferences | Health | Hepatitis | Hepatitis C | Lung Cancer | Merck | Mergers and Aquisitions | Non-Small Cell Lung Cancer | Pharmaceuticals